Abcuro lands $42m

Abcuro Inc, a developer of therapies for autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, has secured $42 million in Series A-1 financing.

Abcuro Inc, a developer of therapies for autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, has secured $42 million in Series A-1 financing. Mass General Brigham Ventures and Sanofi Ventures led the round.

Source: Press Release